Showing results (291-300 of 307) with videos related to

Sort By:
Pageof 31
Neuropsychological Rehabilitation|April 13, 2017
Prevalence of coma-recovery scale-revised signs of consciousness in patients in minimally conscious stateSarah Wannez, Olivia Gosseries, Deborah Azzolini, et al.
Cells|August 10, 2019
Clinical Protocol to Prevent Thrombogenic Effect of Liver-Derived Mesenchymal Cells for Cell-Based TherapiesLouise Coppin, Mustapha Najimi, Julie Bodart, et al.
Annals of Neurology|October 8, 2016
Stratification of unresponsive patients by an independently validated index of brain complexitySilvia Casarotto, Angela Comanducci, Mario Rosanova, et al.
Nature Communications|February 26, 2022
Quantifying arousal and awareness in altered states of consciousness using interpretable deep learningMinji Lee, Leandro R D Sanz, Alice Barra, et al.
International Journal of Molecular Sciences|April 28, 2023
Dexamethasone Modulates the Cytokine Response but Not COVID-19-Induced Coagulopathy in Critically IllMélanie Dechamps, Julien De Poortere, Marie Octave, et al.
Research Square|July 18, 2025
P2RX7 regulates tauopathy progression via tau and mitochondria loading in extracellular vesiclesTsuneya Ikezu, Victor Bodart-Santos, Arun Reddy Ravula, et al.
Biochemical Pharmacology|June 23, 2009
Pharmacology of AMD3465: a small molecule antagonist of the chemokine receptor CXCR4Veronique Bodart, Virginia Anastassov, Marilyn C Darkes, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|May 19, 2023
Alzheimer's disease brain-derived extracellular vesicles reveal altered synapse-related proteome and induce cognitive impairment in miceVictor Bodart-Santos, Lisandra S Pinheiro, Almir J da Silva-Junior, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Mitigating hERG Inhibition: Design of Orally Bioavailable CCR5 Antagonists as Potent Inhibitors of R5 HIV-1 ReplicationRenato Skerlj, Gary Bridger, Yuanxi Zhou, et al.
Bioorganic & Medicinal Chemistry Letters|October 29, 2011
Design and synthesis of pyridin-2-ylmethylaminopiperidin-1-ylbutyl amide CCR5 antagonists that are potent inhibitors of M-tropic (R5) HIV-1 replicationRenato Skerlj, Gary Bridger, Yuanxi Zhou, et al.
Pageof 31